Stock Ratings / Health Care / ZLAB / dividends

BHVN (46) NAMS (38) SUPN (56) MBX (44) ⌘ Pro Terminal →

Zai Lab Limited (ZLAB) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Is ZLAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Zai Lab Limited (NASDAQ: ZLAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $22.36 (-2.95% 1D, market cap $2.51B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZLAB ranks #983 in composite RQD confidence.

Q: How does ZLAB compare to BHVN and NAMS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZLAB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.49B) and NAMS (NewAmsterdam Pharma Company N.V.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B). Among the 5-stock peer group, ZLAB leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for ZLAB?

Per ZLAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704292), Zai Lab Limited generated $457.2M in revenue (+15.0% YoY), -$175.5M in net income, and -$158.9M in free cash flow against $1.17B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is ZLAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ZLAB last traded at $22.36 (-2.95% on volume of 648,529 shares), positioning the stock -10.34% below its 50-day simple moving average ($24.94) and +6.58% above its 200-day simple moving average ($20.98). Across its 52-week range of $15.96 to $27.50, ZLAB sits at the 55.5% percentile with a 14-day RSI of 40.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($19.97 to $24.75).

Q: Does ZLAB pay a dividend and is it safe?

Zai Lab Limited (ZLAB) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$22.36 -2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.20

Zai Lab Limited (ZLAB) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.51B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $22.20 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZLAB)Realized 20D OHLCV Swing Band: ±10.7%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY ZLAB SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 0.52 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (23% of score)

20D Institutional Volume Accumulation (±10.7% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$24.99-7.2% Next Q

Q2 (-2Q)

Grade E$23.19+3.6% Next Q

Q3 (-1Q)

Grade E$24.03-6.9% Next Q

Current

Grade E$22.36-10.5% Hist 90D α

Trajectory: E (34) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZLAB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZLAB currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.94) and Max Pain ($23.48) forces dealer call-delta covering toward $28.88.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZLAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZLAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (8.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $23,243

Est. Year-10 Shareholder Yield: $139/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.9K

Yr 1

$11.8K

Yr 2

$12.9K

Yr 3

$14.0K

Yr 4

$15.2K

Yr 5

$16.6K

Yr 6

$18.0K

Yr 7

$19.6K

Yr 8

$21.4K

Yr 9

$23.2K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZLAB)

✓Walkthrough of ZLAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZLAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.33%📐 WEDGE COMPRESSION COIL

2026-10-30O $22.30H $22.42L $21.80C $22.36VOL 637.8K

RES: $26.60SUP: $21.00SMA50: $24.94SMA200: $20.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZLAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZLAB Butterfly Map → + Track ZLAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +15.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZLAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZLAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZLAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZLAB)

Health Care Rank #983 of 1016 ⚔️ BHVN vs ZLAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZLAB vs. BHVN, NAMS, SUPN, MBX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zai Lab Limited (ZLAB) ranks #983 by composite RQD confidence (26/100, grade E) and #220 by equity capitalization ($2.51B). Within this direct 5-issuer industry benchmark cohort, ZLAB leads on earnings valuation at N/A trailing P/E, while SUPN leads on capital efficiency and profitability with -4.5% ROIC and 89.6% gross margin. SUPN currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with ZLAB at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZLAB ACTIVE Zai Lab Limited	E	26/100	—	58.3%	-35.0%	-2.95%	$2.51B	Benchmark Subject
BHVN Biohaven Ltd.	D	46/100	—	—	-35.0%	+6.25%	$2.49B	/bhvn-vs-zlab →
NAMS NewAmsterdam Pharma Company N.V.	D-	38/100	—	—	-35.0%	-1.47%	$2.48B	/nams-vs-zlab →
SUPN Supernus Pharmaceuticals Inc.	D+	56/100	—	89.6%	-4.5%	+1.85%	$2.43B	/supn-vs-zlab →
MBX MBX Biosciences Inc.	D	44/100	—	—	-26.4%	+0.70%	$2.63B	/mbx-vs-zlab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001704292

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zai Lab Limited (ZLAB) reported GAAP revenue of $457.2M (+15.0% vs. FY2024 revenue of $397.6M , and +71.4% cumulative change since FY2023) , GAAP net income of -$175.5M, operating cash flow of -$150.8M, and free cash flow of -$158.9M (+27.9% YoY). On the balance sheet, ZLAB closed FY2025 with $1.17B in total assets against $0 in total debt (Altman Z-Score: 0.52, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$457.2M	-$175.5M	-$150.8M	-$158.9M	$1.17B	—
FY2024 (FY)	2024-12-31	$397.6M	-$257.1M	-$214.9M	-$220.5M	$1.19B	—
FY2023 (FY)	2023-12-31	$266.7M	-$334.6M	-$198.2M	-$198.2M	—	—

3. ZLAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZLAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Zai Lab Limited (NASDAQ: ZLAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $22.36 (-2.95% 1D, market cap $2.51B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZLAB ranks #983 in composite RQD confidence.

How does ZLAB compare to BHVN and NAMS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZLAB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.49B) and NAMS (NewAmsterdam Pharma Company N.V.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B). Among the 5-stock peer group, ZLAB leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZLAB?

Per ZLAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704292), Zai Lab Limited generated $457.2M in revenue (+15.0% YoY), -$175.5M in net income, and -$158.9M in free cash flow against $1.17B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZLAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ZLAB last traded at $22.36 (-2.95% on volume of 648,529 shares), positioning the stock -10.34% below its 50-day simple moving average ($24.94) and +6.58% above its 200-day simple moving average ($20.98). Across its 52-week range of $15.96 to $27.50, ZLAB sits at the 55.5% percentile with a 14-day RSI of 40.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($19.97 to $24.75).

ZLAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ZLAB pay a dividend and is it safe?

Zai Lab Limited (ZLAB) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ZLAB RQD Cockpit ZLAB 12M Forecast ZLAB Earnings & Move ZLAB Dividends & DRIP ZLAB Insiders & 13F ZLAB Whale Options ZLAB Profit Sankey ZLAB News & Why